Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2018 08:00 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in 2018 Wedbush PacGrow Healthcare Conference

ALPHARETTA, Ga., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
August 08, 2018 07:00 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
August 01, 2018 08:00 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Report Second Quarter 2018 Financial Results on August 8, 2018 – Conference Call to Follow

ALPHARETTA, Ga., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
July 16, 2018 16:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Present Data from its Pivotal Phase 3 (“PEACHTREE”) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

ALPHARETTA, Ga., July 16, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve...
July 11, 2018 16:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs

ALPHARETTA, Ga., July 11, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
June 13, 2018 16:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

ALPHARETTA, Ga., June 13, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
June 11, 2018 17:00 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in 2018 JMP Securities Life Sciences Conference

ALPHARETTA, Ga., June 11, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
May 31, 2018 07:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

Primary and Secondary Endpoints Met in 6-month TrialPatients Treated with CLS-TA Achieved Comparable Vision Improvement With Fewer Treatments ALPHARETTA, Ga., May 31, 2018 (GLOBE NEWSWIRE) --...
May 16, 2018 16:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Present at the 2018 UBS Global Health Care Conference

ALPHARETTA, Ga., May 16, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
May 09, 2018 07:00 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces First Quarter 2018 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., May 09, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding...